Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Over the long term, broad indices tend to outperform many active strategies due to lower costs and market-wide diversification.
27,915 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
A new PC superchip debut sparks a split in stock moves, with Intel and AMD retreating while Nvidia advances on AI dem...
Retail investors on Reddit have shifted to a cautious stance on Tesla as late-2025 results reveal delivery declines a...
Broadcom beat on revenue but missed AI-growth expectations, sparking a rethink on how investors price AI-driven momen...
Teva is shifting from a debt-laden generic player to a branded-focused pharma with a stronger balance sheet. This piv...
Economists say AI is weighing on hiring in the U.S. as the labor market cools, signaling a shift for workers and comp...
A mom of four turns a global role into practical ways families can support kids in need. Learn how to align giving wi...
Friday's strong jobs data complicates the Fed's rate path, signaling higher borrowing costs ahead while raising quest...
The May 2026 Producer Price Index reports a sharp rise in wholesale costs, led by energy inputs, raising the odds of ...
A new class-action alleges that Anthropic overstated Claude Max usage limits and the promised savings. The case could...
When public servants take on off-duty work, the way they’re paid can have real financial consequences. This article u...
As the Fed holds rates, income-focused investors seek reliable yields. This article highlights two dividend stocks ev...